Giri Research

Contact

Name: Veda N. Giri, MD
Position: Professor

1025 Walnut Street
Suite 1015
Philadelphia, PA 19107

Contact Number(s):

Highlighted Publications

Giri VN, Gross L, Gomella LG, Hyatt, C. How I do It: Genetic counseling and genetic testing for inherited prostate cancer. Can J Urol. 2016 Apr; 23(2):8247-53.

Genetic counseling and genetic testing guidelines for prostate cancer are slowly emerging, which emphasizes the need for urologists and other providers involved in the care of prostate cancer patients to consider referring appropriate prostate cancer patients for genetic counseling. This paper highlights the key elements involved in prostate cancer risk assessment, current knowledge of genetic contribution to prostate cancer, and factors for urologists and other providers to consider when referring prostate cancer patients for genetic counseling.

Pilie PG, Giri VN, Cooney KA. HOXB13 and other high penetrant genes for prostate cancer. Asian J Androl 2016; 18:530-2.

Identification of highly penetrant genes in hereditary prostate cancer has proven challenging. However, it is becoming increasingly important to identify these individuals with germline mutations at higher risk for prostate cancer, given that there are no uniformly recommended prostate cancer screening practices for the general population of men in the United States.

Nicolas E, Arora S, Zhou Y, Serebriiskii IG, Andrake MD, Handorf ED, Bodian DL, Vockley JG, Dunbrack RL, Ross EA, Egleston BL, Hall MJ, Golemis EA, Giri VN, Daly MB. Systematic evaluation of underlying defects in DNA repair as an approach to case-only assessment of familial prostate cancer. Oncotarget. 2015 Nov 24; 6(37):39614-33.

The goal of this study was to develop an operational framework to select and evaluate gene variants that may contribute to familial prostate cancer risk. This work suggests the value of focusing on underlying defects in DNA damage in familial prostate cancer risk assessment and demonstrates an operational framework for exome sequencing in case-only prostate cancer genetic evaluation.

Hall MJ, Forman AD, Pilarski R, Wiesner G, Giri VN. Gene panel testing for inherited cancer risk. J Natl Compr Canc Netw. 2014 Sep; 12(9):1339-46. Review.

This article describes the many gene panel testing options clinically available to assess inherited cancer susceptibility, the potential advantages and challenges associated with various types of panels, clinical scenarios in which gene panels may be particularly useful in cancer risk assessment, and testing and counseling considerations.

Handorf E, Crumpler N, Gross L, Giri VN. Prevalence of the HOXB13 G84E mutation among unaffected men with a family history of prostate cancer. J Genet Couns. 2014 Jun; 23(3):371-6.

The goal of this analysis was to assess the prevalence of the HOXB13 G84E mutation in ethnically-diverse high-risk men undergoing prostate cancer screening and place the carrier frequency within the context of prevalence estimates from reported studies to gain insight into the future role of this mutation in genetic counseling. While the HOXB13 G84E mutation may be rare, there may be a future role in genetic testing for this mutation after further studies of clinical utility in assessing prostate cancer risk.

Recent Publications

Helix: A Digital Tool to Address Provider Needs for Prostate Cancer Genetic Testing in Clinical Practice

When to Use Germline Genetic Testing in Prostate Cancer

Germline testing and genetic counselling in prostate cancer

Genetic testing in prostate cancer management: Considerations informing primary care

Prostate Cancer Genetics: Changing the Paradigm of Care

Genetic Testing Guidelines and Education of Health Care Providers Involved in Prostate Cancer Care

Barriers and facilitators of germline genetic evaluation for prostate cancer

Gaps in Public Awareness about BRCA and Genetic Testing in Prostate Cancer: Social Media Landscape Analysis

Physical activity assessment among men undergoing genetic counseling for inherited prostate cancer: a teachable moment for improved survivorship

Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer

Testing a Prostate Cancer Educational Intervention in High-Burden Neighborhoods

Pretest genetic education video versus genetic counseling for men considering prostate cancer germline testing: A patient-choice study to address urgent practice needs

Philadelphia Prostate Cancer Genetic Consensus Conference 2019 and implications for military medicine

Practical considerations and challenges for germline genetic testing in patients with prostate cancer: Recommendations from the germline genetics working group of the PCCTC

Cancer Screening and Genetic Testing Recommendations for Relatives of Men Undergoing Prostate Cancer Germline Testing: Implications for Practice

Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019

The effect of neighborhood social environment on prostate cancer development in black and white men at high risk for prostate cancer

Exploring Asian Indian views about cancer and participation in cancer research: an evaluation of a culturally tailored educational intervention

Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation✰,✰✰

Introduction to the 2019 Philadelphia Prostate Cancer Consensus Program: 'Implementation of Genetic Testing for Inherited Prostate Cancer'

Genetic education and practice considerations of non-genetic providers

Modification of the base excision repair enzyme MBD4 by the small ubiquitin-like molecule SUMO1

Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium

Diet assessment among men undergoing genetic counseling and genetic testing for inherited prostate cancer: Exploring a teachable moment to support diet intervention

Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing